Gavi is co-leading COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator. This involves coordinating the COVAX Facility, a global risk-sharing mechanism for pooled procurement and equitable distribution of COVID-19 vaccines.
The ACT Accelerator is a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines.
COVAX is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi and the World Health Organization (WHO), alongside key delivery partner UNICEF. Its aim is to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee fair and equitable access for every country in the world.
For any enquiries about the COVAX Facility, please contact email@example.com.
Gavi’s Board Meeting emphasizes public health impact with renewed push for routine immunization and reaching zero-dose children.
COVAX has access to enough COVID-19 vaccines to help protect 70% of the population in 91 lower-income countries
The White House today announced that US International Development Finance Corporation (DFC) and Gavi, the Vaccine Alliance have partnered to create the COVAX Rapid Financing Facility, which will provide up to US$ 1 billion to accelerate COVID-19…
Summit sees US$ 4.8 billion in commitments, securing vital cash to help lower income countries boost vaccinations now, secure equitable access for new vaccine procurements plus additional help for countries looking to procure their own vaccines…
This new partnership comes as Gavi seeks to raise additional funds to support COVAX. April 8 will see Germany, Indonesia and Senegal co-host the 2022 Gavi COVAX AMC Summit, where governments, international organisations, civil society and the…
The governments holding the presidencies of the G7, the G20 and the African Union will co-host a summit to raise new urgent funding for global vaccination in lower-income economies, a sign of renewed international cooperation and a continued…
Germany will co-host the 2022 AMC Summit to help raise urgent funding to support lower-income countries’ dynamic COVID-19 vaccination needs.
31 countries have contributed to the effort, which accounts for nearly half of COVAX’s total shipments of over 1.1 billion doses – of which more than a billion have been distributed to lower-income economies supported through the Gavi Advance…
COVAX, the vaccine pillar of the Access to COVID-19 Tools Accelerator (ACT-Accelerator), has now shipped over 1 billion doses to 144 countries and territories.
Geneva, 21 December 2021 – The COVAX Facility has been awarded the 2021 North-South Prize of the Council of Europe in recognition of its efforts to ensure that COVID-19 vaccines are available worldwide, including in low-income countries, and for…
Agreement will make up to an additional 150 million doses of the Moderna COVID-19 vaccine available to COVAX Facility participants in Q2 and Q3 2022, at the lowest tiered price.
A new malaria vaccination programme has been approved, providing Gavi-eligible countries in sub-Saharan Africa a powerful new tool with which to fight malaria.
One of the first COVAX funders and first dose donors, New Zealand has again stepped up and pledged NZ$ 9 million in funding to the Gavi COVAX Advance Market Commitment (Gavi COVAX AMC). This funding will help COVAX better respond to country needs…
Building on lessons learned from our collective experience with dose donations over the past several months, the African Vaccine Acquisition Trust (AVAT), the Africa Centres for Disease Control and Prevention (Africa CDC) and COVAX wish to draw…
As part of a pledge of 500 million doses by Team Europe, eight EU Member States have donated doses of the AstraZeneca, Johnson & Johnson and Pfizer vaccines to COVAX to support lower-income economies around the world in the fight against the…
Switzerland becomes first country to respond to call to trade places with COVAX in manufacturers’ supply queues.
The first shipments of almost 100 million doses of the Johnson & Johnson vaccine from Team Europe are arriving in a number of African countries. This donation is facilitated by a tripartite agreement between Belgium (acting on behalf of Team…
As part of a 409,600-dose pledge to COVAX, Rwanda has become the first country to receive COVID-19 vaccines donated by Luxembourg, receiving 12,000 doses of the AstraZeneca vaccine. This commitment is part of a Team Europe pledge to donate 500…
Geneva/New York, 16 November 2021 – Gavi, the Vaccine Alliance (Gavi) and the member agencies of the Inter-Agency Standing Committee (IASC) the humanitarian system’s main coordinating body1, are working together to ensure that the most vulnerable…
The first shipments of a 3 million dose pledge to COVAX thus far by Greece have arrived in Kenya (376,800 doses) and Syria (144,000). This builds on previous funding commitments of EUR 1.5 million to the Gavi COVAX Advance Market Commitment (Gavi…
As part of a pledge to share at least 3.65 million doses of COVID-19 vaccines with lower-income economies through COVAX, Finland’s donation has begun with a first delivery of 98,400 doses of the AstraZeneca vaccine to Côte d’Ivoire.
As part of a pledge to share at least 5% of domestic supply of vaccines with its development partners, the first doses donated by Portugal through COVAX have reached Senegal.
This Monday morning, 11 October, Mr Serge Dal Busco, President of the Council of State of Geneva, symbolically awarded the parcel of the Vigne des Nations to Gavi, the Vaccine Alliance. This recognition honours the commitment of this organisation…
The first shipment of a Swiss donation of 4 million doses has arrived in Sierra Leone, with 24,000 doses of the AstraZeneca vaccine touching down in Freetown on 9 October 2021.
Gulf Cooperation Council (GCC) countries have come together to support global equitable access to COVID-19 vaccines, with pledges now totalling US$ 221 million in funding pledges and US$ 50 million in in-kind support from all six Member States,…
The Gavi Board met yesterday to discuss the impact of the pandemic on routine immunisation and how COVAX can best support countries’ efforts to control the pandemic, as part of a broader consultative process to develop the 2022 COVAX strategy
Leaders pledge financing, dose donations, support for country readiness and delivery and scale up of global manufacturing, to enable equitable access to COVID-19 vaccines.
U.S. International Development Finance Corporation, in conjunction with Citi, launch risk management solution for COVAX Facility.
As part of a donation of 125,726 doses to COVAX, the first shipment of 35,700 doses of the AstraZeneca vaccine donated by Iceland has arrived in Côte d’Ivoire.
As part of its pledge to deliver 15 million doses of COVID-19 vaccines, the first doses donated by Italy have been delivered to Iraq, with more shipping to additional countries in the coming days.
Building on its pledge of EUR 1.62 billion to COVAX, the German government has donated the first batch of its pledge of 100 million doses of COVID-19 vaccines, the majority of which will be delivered via COVAX.
COVAX has already achieved significant progress: more than US$10 billion has been raised; legally-binding commitments for up to 4.5 billion doses of vaccine; 240 million doses have been delivered to 139 countries in just six months.
As part of its pledge to deliver 4 million doses of COVID-19 vaccines, the first doses donated by Belgium have been delivered to Armenia.
Three countries in Africa will receive the first Canadian-donated doses of the AstraZeneca vaccine – Nigeria (801,600 doses), Kenya (459,300) and Niger (100,800) – as part of an overall Canadian pledge of over 40 million doses to COVAX
African Union Member States are to receive an additional 10 million doses of Astra Zeneca and Pfizer COVID-19 vaccines through COVAX and the Africa Vaccine Acquisition Trust (AVAT), thanks to a new arrangement with the French government and the…
The first deliveries from a pledge of 1 million doses to be donated to COVAX by Denmark have arrived, with 57,600 doses of the AstraZeneca (AZ) vaccine to Algeria on 26 August.
The first AstraZeneca doses donated to COVAX by the United Kingdom (UK) will soon arrive in Angola, Egypt, Ethiopia, Ghana, Kenya, Malawi, Nigeria, Senegal and Uganda, with Zambia and DRC set to be the first to receive these UK-donated vaccines…
The Government of the People’s Republic of China (China) has pledged US$100 million to the Gavi COVAX Advance Market Commitment (Gavi COVAX AMC). The announcement, made at the International Forum on COVID-19 Vaccine Cooperation, hosted by China,…
As part of its pledge to deliver 22.5 million doses of COVID-19 vaccines, the first doses donated by Spain are arriving to countries in Latin America.
Gavi, MedAccess and GlaxoSmithKline join forces to guarantee continued production of the RTS,S antigen for the RTS,S/AS01e malaria vaccine.
As part of a pledge to deliver at least three million doses of COVID-19 vaccines, the first doses donated by Sweden have been delivered to countries this week, with shipments arriving in Kyrgyzstan and Afghanistan
Norway donates first doses to COVAX, with first shipments arriving in Nicaragua and Uganda on 30 July. In total, Norway has pledged 5 million doses to COVAX, as well as US$ 141 million in funding.
COVAX and the World Bank will accelerate COVID-19 vaccine supply for developing countries through a new financing mechanism that builds on Gavi’s newly designed AMC cost-sharing arrangement. This allows AMC countries to purchase doses beyond the…
The first COVID-19 vaccine doses donated by Japan to the Gavi COVAX Advance Market Commitment (Gavi COVAX AMC) have been shipped, with first shipments set to arrive in Cambodia and Iran on Friday, 23 July, and Bangladesh on Saturday, 24 July.
16 July 2021 – Following close collaboration between the African Union (AU)/ African Vaccine Acquisition Trust (AVAT), COVAX and the United States Government, AU Member States are set to receive approximately 25 million COVID-19 vaccines to…
Gavi, the Vaccine Alliance announced today that it had signed advance purchase agreements (APAs) with Sinopharm for its “BBIBP-CorV” inactivated virus vaccine against COVID-19 as well as with Sinovac for its inactivated virus vaccine against…
Geneva/New York/Oslo, 01 July 2021 – COVAX was built on the principle of equitable access to COVID-19 vaccines to protect the health of people all across the globe. That means protecting their lives and livelihoods, including their ability to…
Geneva, 30 June 2021 – Gavi, the Vaccine Alliance announced today that it had signed an advance purchase agreement (APA) with Clover Biopharmaceuticals for its SCB-2019 protein-based adjuvanted vaccine candidate against COVID-19. The agreement…
Geneva, 27 June 2021 – Following announcements in recent weeks of donation pledges by the Biden-Harris Administration, COVAX is preparing to ship doses of COVID-19 vaccines donated to COVAX by the United States Government to protect at-risk…
The forecast is encouraging given the supply disruptions COVAX and countries with bilateral deals are currently experiencing, and the general challenges manufacturers are experiencing as they ramp up supply at historic speed and scale.
The Republic of Korea has announced a pledge of US$ 200 million to the Gavi COVAX Advance Commitment (Gavi COVAX AMC), with US$ 100 million to be provided in 2021 and an additional US$ 100 million to be provided in 2022
COVAX welcomes dose sharing commitments for 870 million additional doses to support equitable access to vaccines in 2021 and 2022, with the aim to deliver at least half by the end of 2021.
Geneva, 10 June 2021 – Gavi, the Vaccine Alliance, today welcomes the decision by the United States Government to procure 500 million COVID-19 vaccine doses on behalf of the COVAX Facility.
Gavi, the Vaccine Alliance, welcomes the announcement by the United States Government of its strategy for global vaccine sharing, which sets out how it will provide at least 80 million doses of vaccines to the rest of the world – with the…
The Gavi COVAX AMC Summit “One World Protected” virtual event, hosted today by the Government of Japan and Gavi, the Vaccine Alliance, raised US$ 2.4 billion from nearly 40 donor governments, the private sector and foundations, exceeding the…
Responding to an urgent need for doses around the world, the Government of New Zealand has pledged to transfer 1.6 million doses allocated through COVAX to lower-income economies.
Countries that are advanced in their vaccination programmes are seeing cases of COVID-19 decline, hospitalisations decrease and early signs of some kind of normality resume. However, the global picture is far more concerning.
At today’s Global Health Summit, hosted by the European Commission and Italy as chair of the G20, leaders pledged their support to the Gavi COVAX Advance Market Commitment (AMC).
The signed advance purchase agreement (APA) is for a commitment to purchase 200 million doses of the Johnson & Johnson vaccine, with the goal of them being made available to the COVAX Facility in 2021.
Individuals can now directly fund vaccines for lower-income countries via the Gavi COVAX AMC to help end the pandemic. The platform will give businesses a chance to match employee and customer contributions.
Geneva, 12 May 2021 – The Government of Japan yesterday announced that it will host the virtual Gavi COVAX Advance Market Commitment (AMC) Summit on June 2nd 2021. The event, co-hosted by Japanese Prime Minister H.E.
The pledges were announced at Global Citizen’s Vax Live Concert on Saturday, co-hosted by Selena Gomez and featuring messages from Prince Harry, the Duke of Sussex, His Holiness Pope Francis and several Heads of State
The signed advance purchase agreement (APA) is for a commitment to purchase 350 million doses of the Novavax vaccine candidate. Deliveries will commence in Q3 2021, upon regulatory approval.
The signed advance purchase agreement (APA) is for up to 500 million doses of the COVID-19 vaccine manufactured by Moderna. Supply via the agreement will take place from the second half of 2021 through 2022, with options in place to address the…
Geneva/New York, 26 April 2021 – While immunization services have started to recover from disruptions caused by COVID-19, millions of children remain vulnerable to deadly diseases, the World Health Organization (WHO), UNICEF and Gavi, the Vaccine…
Today, to mark the first year of the creation of the Access to COVID-19 Tools (ACT) Accelerator, President Emmanuel Macron announced that France has begun sharing vaccine doses with COVAX, starting with a first batch of 105,600 doses – with 500,…
The “One World Protected” Event, hosted today by the United States and Gavi, the Vaccine Alliance, launched a campaign to raise US$ 2 billion for the global fight against COVID-19.
The COVAX Facility has now delivered life-saving vaccines to over 100 economies since making its first international delivery to Ghana on February 24th.
The partnership will focus on reaching children who are currently receiving no routine vaccines and marginalised communities in line with Gavi’s vision to ‘leave no-one behind with immunisation’.
The virtual event will bring together world leaders, the private sector, civil society, and key technical partners to galvanize resources and commitment to the Gavi COVAX Advance Market Commitment (AMC).
The COVAX Facility has notified participating economies that deliveries of doses from the Serum Institute of India (SII) will be delayed in March and April.
Geneva/Oslo/New York, 2 March 2021 – The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance (Gavi) and the World Health Organization (WHO), as co-leads of the COVAX initiative for equitable global access to COVID-…
Today, the governments of Côte d’Ivoire and Ghana began COVID-19 vaccination campaigns aimed at protecting healthcare workers
COVAX announces 600,000 doses of the AstraZeneca/Oxford vaccine licensed to Serum Institute of India have arrived in Accra, Ghana; further deliveries to Abidjan, Cote d’Ivoire are expected this week.
New programme makes compensation available to eligible individuals in 92 low- and middle-income countries without need to resort to law courts.
Today G7 leaders announced a doubling of funding for Gavi COVAX AMC to support lower-income economies obtain life-saving vaccines against COVID-19, ensuring greater equity in fighting to end the acute phase of the pandemic.
The signed memorandum of understanding (MoU) between Gavi and Novavax is to make a cumulative volume of 1.1 billion doses of the Novavax vaccine candidate available to the COVAX Facility.
Geneva / New York / Oslo – 15 February 2021 The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance (Gavi) and the World Health Organisation (WHO), as co-leads of the COVAX initiative for equitable global access to…
The emergence of variants of SARS-CoV-2, the virus that causes COVID-19, serve as a powerful reminder that viruses by their very nature mutate, and that the scientific response may need to adapt if they are to remain effective against them.
Geneva/Oslo/New York, 3 February 2021 – The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance and the World Health Organisation, as co-leads of the COVAX initiative for equitable global access to COVID-19 vaccines…
COVAX announced the signing of an advance purchase agreement for up to 40 million doses of the Pfizer-BioNTech vaccine; rollout to commence with successful execution of supply agreements.
COVAX now has agreements in place to access nearly two billion doses of several promising vaccine candidates, and laid the groundwork for further doses to be secured through contributions from donors.
Gavi Board approves more than US$ 600 million in new funding to help accelerate efforts to reach ‘zero-dose’ and under-immunised children in the face of the COVID-19 pandemic.
High-risk and vulnerable groups and healthcare workers first in line for successful vaccine.
Memorandum of understanding signed today will strengthen collaboration on vaccination efforts and related health services for migrants and forcibly displaced persons across the world
Geneva, 24 November 2020 – Gavi, the Vaccine Alliance, as co-lead of COVAX and administrator of the COVAX Facility, welcomes the release of interim efficacy data for the AstraZeneca/Oxford COVID-19 vaccine candidate.
The COVAX AMC Engagement Group, composed of Gavi COVAX AMC participants, donors, and other stakeholders, forms a key component of Facility governance.
The European Commission, France, Spain, The Republic of Korea and the Bill & Melinda Gates Foundation pledge US$ 360 million to Gavi’s COVID-19 Vaccines Advance Market Commitment (COVAX AMC)
The COVAX Shareholders Council, composed of all self-financing participants, forms a key component of Facility governance.
As part of the global response to the COVID-19 pandemic, COVAX – the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, co-led by Gavi, CEPI, and the WHO – welcomes the appointment of civil society organisation representatives to…
Gavi, the Vaccine Alliance announced today that it had signed a Statement of Intent with Sanofi and GSK to provide 200 million doses of the companies’ adjuvanted recombinant protein COVID-19 vaccine to the COVAX Facility.
Japanese Government pledges US$ 130 million in funding to the Gavi COVAX Advance Market Commitment (AMC), bringing the total raised to roughly US$ 1.8 billion.
The United Kingdom, Canada, Germany, Italy and Sweden pledge approximately US$ 960 million to Gavi’s COVID-19 Vaccines Advance Market Commitment (COVAX AMC)
The Gavi Board has approved the provision of US$ 150 million in initial funding to jumpstart support COVAX AMC-eligible countries’ readiness to deliver COVID-19 vaccines, in the form of planning, technical assistance and cold chain equipment
Collaboration among the Serum Institute of India (SII), Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation will accelerate manufacturing and delivery of up to an additional 100 million doses of future vaccines, if proven to be…
64 higher income economies have now joined the COVAX Facility, with a further 38 economies expected to sign in the coming days
The funding will support the Gavi COVAX Advance Market Commitment (AMC), which aims to secure doses of COVID-19 vaccines for 92 low- and middle-income countries and economies at the same time as wealthier nations
Goal of bringing the pandemic under control via equitable access to COVID-19 vaccines needs urgent, broadscale commitment and investment from countries
CSOs will play a vital role in the development and implementation of the COVAX initiative as well as the deployment of any successful vaccine through COVAX.
New landmark collaboration between the Serum Institute of India (SII), Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation to accelerate manufacturing and delivery of up to 100 million doses of future safe and effective COVID-…
Gavi Board agrees scope of COVAX Advance Market Commitment (AMC), which aims to secure doses of COVID-19 vaccines for 92 low- and middle-income countries and economies at the same time as wealthier nations.
Seventy-five countries submit expressions of interest to COVAX Facility, joining up to 90 further countries which could be supported by the COVAX Advance Market Commitment (AMC)
Global technology company TransferWise and a donor which asked to remain anonymous made significant financial commitments to Gavi’s Advance Market Commitment for COVID-19 Vaccines (Gavi COVAX AMC)
Gavi Board shows support for continued work on COVAX Facility: a global, coordinated mechanism designed to ensure rapid and equitable access to safe and efficacious COVID-19 vaccines to as broad a global population as possible
Gavi Advance Market Commitment for COVID-19 Vaccines (Gavi Covax AMC) launched at Global Vaccine Summit 2020 draws strong support, early commitments from global leaders.
The Humanitarian Buffer is a mechanism established within the COVAX Facility to act as a measure of ‘last resort’ to ensure access to COVID-19 vaccines for high-risk and vulnerable populations in humanitarian settings. Populations of concern in humanitarian settings may include refugees, asylum seekers, stateless persons, internally displaced persons, minorities, populations in conflict settings or those affected by humanitarian emergencies, and vulnerable migrants irrespective of their legal status. Both COVAX Participants and humanitarian agencies can apply for Humanitarian Buffer doses.
To date, Gavi has secured indemnity and liability requirement waivers for seven vaccines within the COVAX portfolio for deployment by Humanitarian Agencies. The Humanitarian Buffer has access to the following vaccine products:
N.B. While application review, approval, prioritisation and allocation will be undertaken on an ongoing basis by the IASC decision-making body, applicants are advised that shipment of doses is contingent on available supply and successful contracting with manufacturers:
Supply constraints affecting the COVAX Facility will also impact the availability of doses to the Humanitarian Buffer.
Shipments for humanitarian agencies, including UN organisations, Red Cross and Red Crescent, International and national non-governmental and civil society organisations, are subject to successful conclusion of contracts with manufacturers, including on indemnity and liability-related arrangements.
COVAX Humanitarian Buffer applications are for doses, devices and delivery funding, as required. For any questions, or to submit an application, please contact COVAX_Humanitarian_Buffer@gavi.org.
Gavi, the Vaccine Alliance is the legal administrator of the COVAX Facility, and has overseen the establishment of the COVAX Facility Advance Market Commitment (AMC) Engagement Group - a governance body comprising economies that are eligible for COVID-19 vaccines through the Gavi COVAX AMC - and the COVAX Facility Shareholders Council - composed of self-financing participants.
Mandate: Established by the Gavi Board to convene representatives from implementing countries, donors and other parties engaged in the financing and operation of the AMC portion of the Facility, with the aim of providing strategic guidance and advice to the Office of the COVAX Facility on the operational aspects of the COVAX Facility.
Membership: Open to all implementing countries, donors, other partners engaged in financing and operations of the AMC portion of the Facility. A representative from each of WHO, PAHO, UNICEF, the World Bank, and Civil Society has a permanent observer seat.
Retno L.P. Marsudi
Mandate: Established by the Gavi Board to convene Self-Financing Participants (SFPs) of the COVAX Facility with the aim of providing strategic guidance and advice to the Office of the COVAX Facility on the operational aspects of the COVAX Facility. It receives regular updates from the Office of the COVAX Facility, including reports on allocation decisions and overall activities, and decisions or recommendations made by technical bodies (MSDC, Independent Product Group, Procurement Reference Group and Independent Allocation Validation Group) and the Board.
Membership: Open to all SFPs. A representative from each of WHO, PAHO, UNICEF, the World Bank, Civil Society and the AMC92 Group has a permanent observer seat.
Dr. Chrysoula Zacharopoulou
Dr. Fernando Ruiz
Developing a vaccine against COVID-19 is the most pressing challenge of our time - and nobody wins the race until everyone wins.
The global pandemic has already caused the loss of hundreds of thousands of lives and disrupted the lives of billions more. As well as reducing the tragic loss of life and helping to get the pandemic under control, introduction of a vaccine will prevent the loss of US$ 375 billion to the global economy every month. Global equitable access to a vaccine, particularly protecting health care workers and those most-at-risk is the only way to mitigate the public health and economic impact of the pandemic.
Gavi is coordinating the development and implementation of the COVAX Facility, the global procurement mechanism of COVAX. The COVAX Facility will make investments across a broad portfolio of promising vaccine candidates (including those being supported by CEPI) to make sure at-risk investment in manufacturing happens now. This means the COVAX Facility, by pooling purchasing power from all countries that participate, will have rapid access to doses of safe and effective vaccines as soon as they receive regulatory approval. Guided by an allocation framework being developed by WHO, the COVAX Facility will then equitably distribute these doses to help protect the most at-risk groups in all participating countries.
Gavi is coordinating the development and implementation of the COVAX AMC, the financing instrument that will support the participation of 92 lower-middle and low-income economies in the COVAX Facility. The COVAX AMC is critical to ensuring equitable access to COVID-19 vaccines, regardless of income level – and requires an urgent investment of US$ 2 billion, from sovereign donors, philanthropies and the private sector, by the end of 2020. The COVAX AMC and associated support to the eligible countries that apply will build on Gavi’s two decades of experience delivering life-saving vaccines to more than half of the world’s population, including in the hardest to reach communities.
- Country readiness & delivery
Gavi is working with Alliance partners UNICEF and WHO to ensure that the infrastructure is in place, and the technical support available, to make sure COVID-19 vaccines can be safely delivered to all those who need them. Gavi is also part of the health systems work of the ACT-Accelerator effort, focusing on areas where it has expertise and experience, such as cold chain.
Kenya was aiming to reach 10 million people with COVID-19 vaccines by the end of December 2021. Thanks to a clear strategy, COVAX support and the hard work of thousands of health workers, they reached their target.
Without it we could face further delays in the global rollout and risk the gulf between the vaccine haves and have nots widening.
COVAX and the other international organizations committed to vaccine equity cannot end the COVID-19 pandemic without the continued support of governments, industry, and civil society. By working together, the world has a chance to tame the…
Vaccination started off slow, but has steadily increased over 2021 thanks to public health messaging and vaccine deliveries.
All around the world, COVAX deliveries are helping to protect frontline health workers, reach nomadic communities, reunite families and allow schools to reopen. Since deliveries began in March, #VaccinesWork has been publishing snapshots that…
People around the world have demonstrated global solidarity by donating to the COVAX Facility, providing vaccines to those who would otherwise have no access.